IL161997A - Pharmaceutical composition comprising a 5ht1 receptor agonist - Google Patents

Pharmaceutical composition comprising a 5ht1 receptor agonist

Info

Publication number
IL161997A
IL161997A IL16199702A IL16199702A IL161997A IL 161997 A IL161997 A IL 161997A IL 16199702 A IL16199702 A IL 16199702A IL 16199702 A IL16199702 A IL 16199702A IL 161997 A IL161997 A IL 161997A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
receptor agonist
agonist
receptor
pharmaceutical
Prior art date
Application number
IL16199702A
Other languages
English (en)
Other versions
IL161997A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL161997A0 publication Critical patent/IL161997A0/xx
Publication of IL161997A publication Critical patent/IL161997A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16199702A 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist IL161997A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129117.8A GB0129117D0 (en) 2001-12-05 2001-12-05 Pharmaceutical composition
PCT/EP2002/013715 WO2003047552A2 (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Publications (2)

Publication Number Publication Date
IL161997A0 IL161997A0 (en) 2005-11-20
IL161997A true IL161997A (en) 2005-12-18

Family

ID=9927051

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16199702A IL161997A (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Country Status (29)

Country Link
US (1) US20050032867A1 (de)
EP (2) EP1450770B1 (de)
JP (1) JP3699969B2 (de)
KR (1) KR100591237B1 (de)
CN (1) CN1289069C (de)
AR (1) AR037627A1 (de)
AT (1) ATE291900T1 (de)
AU (1) AU2002358602B2 (de)
BR (1) BR0214497A (de)
CA (1) CA2469019C (de)
CO (1) CO5580741A2 (de)
DE (1) DE60203537T2 (de)
ES (1) ES2236608T3 (de)
FI (1) FI20022128A (de)
GB (1) GB0129117D0 (de)
HK (1) HK1069111A1 (de)
HU (1) HU229313B1 (de)
IL (1) IL161997A (de)
IS (1) IS2481B (de)
MX (1) MXPA04005420A (de)
MY (1) MY129314A (de)
NO (1) NO329896B1 (de)
NZ (1) NZ532829A (de)
PL (1) PL194702B1 (de)
PT (1) PT1450770E (de)
RU (1) RU2285526C2 (de)
TW (1) TWI240638B (de)
WO (1) WO2003047552A2 (de)
ZA (1) ZA200403849B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
MXPA05010070A (es) 2003-04-11 2005-11-23 Pfizer Combinacion farmaceutica.
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
EP1750677B1 (de) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP3263117A1 (de) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
US20070259040A1 (en) * 2006-05-01 2007-11-08 Cherukuri S R Novel triptan formulations and methods for making them
US20080081072A1 (en) * 2006-09-30 2008-04-03 Cherukuri S R Resin-complex granulation for water-soluble drugs and associated methods
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027827D0 (en) * 1990-12-21 1991-02-13 Glaxo Laboratoires Pharmaceutical compositions
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
AU2640599A (en) * 1998-02-26 1999-09-15 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1246668B1 (de) * 1999-12-01 2005-11-30 Natco Pharma Limited Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine

Also Published As

Publication number Publication date
DE60203537D1 (de) 2005-05-04
CA2469019C (en) 2005-09-13
AU2002358602B2 (en) 2005-05-26
BR0214497A (pt) 2004-10-19
NO20025805L (no) 2003-06-06
EP1450770B1 (de) 2005-03-30
AU2002358602A1 (en) 2003-06-17
HK1069111A1 (en) 2005-05-13
HU229313B1 (en) 2013-10-28
AR037627A1 (es) 2004-11-17
MY129314A (en) 2007-03-30
KR100591237B1 (ko) 2006-06-19
HUP0402178A2 (hu) 2005-02-28
NO329896B1 (no) 2011-01-24
MXPA04005420A (es) 2004-10-11
JP3699969B2 (ja) 2005-09-28
IS7293A (is) 2004-06-03
EP1527773A1 (de) 2005-05-04
CN1289069C (zh) 2006-12-13
CA2469019A1 (en) 2003-06-12
JP2005515991A (ja) 2005-06-02
TWI240638B (en) 2005-10-01
RU2004120292A (ru) 2005-04-10
HUP0402178A3 (en) 2011-05-30
ATE291900T1 (de) 2005-04-15
FI20022128A0 (fi) 2002-12-03
GB0129117D0 (en) 2002-01-23
US20050032867A1 (en) 2005-02-10
NZ532829A (en) 2005-05-27
CO5580741A2 (es) 2005-11-30
PL194702B1 (pl) 2007-06-29
ES2236608T3 (es) 2005-07-16
CN1610539A (zh) 2005-04-27
TW200304384A (en) 2003-10-01
WO2003047552A3 (en) 2003-09-25
KR20050044720A (ko) 2005-05-12
IL161997A0 (en) 2005-11-20
NO20025805D0 (no) 2002-12-03
ZA200403849B (en) 2005-10-26
WO2003047552A2 (en) 2003-06-12
EP1450770A2 (de) 2004-09-01
PL370669A1 (en) 2005-05-30
RU2285526C2 (ru) 2006-10-20
FI20022128A (fi) 2003-06-06
PT1450770E (pt) 2005-08-31
IS2481B (is) 2008-12-15
DE60203537T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
AU1845402A (en) Nmda receptor agonist pharmaceutical compositions
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
EP1385486A4 (de) Neuartiger überzug für eine pharmazeutische zusammensetzung mit verzögerter freisetzung
GB2394894B (en) New use for pharmaceutical composition
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
EP1411904A4 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
EP1408896A4 (de) Pharmazeutische zusammensetzung
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
HUP0200057A3 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
SI1347760T1 (en) Nmda receptor agonist pharmaceutical compositions
AU2002342940A8 (en) New pharmaceutical compounds
GB0130576D0 (en) Dopamine D1 receptor agonist pro-drug compounds & derivatives
GB0201919D0 (en) A�-Adenosine receptor agonists
GB0201849D0 (en) A�- adenosine receptor agonists
IL166080A0 (en) Sustained-release tablet composition comprising a dopamine receptor agonist
AU2002338040A1 (en) Receptor antagonist

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed